Latest news with #APLS
Yahoo
a day ago
- Business
- Yahoo
Apellis, Sobi present data from open-label period of Phase 3 VALIANT study
Apellis Pharmaceuticals (APLS) and Sobi (BIOVF) presented new data from the open-label period of the Phase 3 VALIANT study, investigating EMPAVELI for C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis. The data were presented as part of a late-breaking session at the European Renal Association Congress. In the VALIANT study, EMPAVELI demonstrated a statistically significant 68% proteinuria reduction versus placebo at Week 26, which was sustained at one year. Additionally, patients treated with EMPAVELI continued to achieve stabilization of kidney function as measured by estimated glomerular filtration rate. 'The one-year Phase 3 results are very compelling, confirming EMPAVELI's sustained benefits across key markers of disease,' said Fadi Fakhouri, presenting author, co-lead principal investigator for the VALIANT study, and professor of nephrology at CHUV Lausanne. 'Given the high risk of kidney failure, treatment efficacy is incredibly important to C3G and primary IC-MPGN patients, many of whom are in the prime of their lives. These data further underscore the potential of EMPAVELI to make a meaningful difference for patients.' In patients who switched from placebo to EMPAVELI at the start of the open-label period, EMPAVELI demonstrated a similar magnitude of benefit in proteinuria reduction and stabilization of kidney function. EMPAVELI showed favorable safety and tolerability, consistent with its established profile. There were no new safety signals. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on APLS: Disclaimer & DisclosureReport an Issue Apellis Pharmaceuticals Holds Annual Stockholders Meeting Apellis price target raised to $29 from $26 at Wells Fargo Cautious Hold on Apellis Pharmaceuticals Amid Uncertainties with Pegcetacoplan Launch and Financial Stability Apellis price target lowered to $41 from $49 at Citi Apellis price target lowered to $20 from $30 at Mizuho Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 days ago
- Business
- Yahoo
Why Apellis Pharmaceuticals, Inc. (APLS) Skyrocketed On Monday
We recently published a list of . In this article, we are going to take a look at where Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stands against other top-performing stocks on Monday. Apellis Pharmaceuticals surged by 13.05 percent on Monday to finish at $19.14 apiece after earning a higher price target from an investment firm. On Monday, Wells Fargo raised its price target for the company to $29 from $26 previously, while maintaining an 'equal weight' rating for the stock. Wells Fargo said that the adjustment reflected its optimism about Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) potential treatment for rare kidney diseases C3G and IC-MPGN, which could bolster opportunities for the company. A biomedical scientist in a lab coat conducting research on biopharmaceutical compounds. Wells Fargo expected the treatment to secure an approval, but underscored the need for a clearer understanding of its potential downside risks before becoming more optimistic on the stock. In the first quarter of the year, Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) widened its net loss by 39 percent to $92 million from $66 million in the same period last year. Revenues inched up by 3 percent to $166.8 million from $172.3 million year-on-year. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
27-05-2025
- General
- Yahoo
Alabama Library Association ‘concerned but also confused' by new APLS content policies
Signs are posted in the young adult section of the Autauga-Prattville Public Library on Feb. 23, 2024. The Alabama Library Association said in a letter earlier this month it was "concerned but also confused" by new definitions of the term "sexually explicit" by the Alabama Public LIbrary Service board. (Ralph Chapoco/ Alabama Reflector) The Alabama Library Association said in a May 16 letter that it was 'concerned but also confused' by new Alabama Public Library Service policies on sexually explicit content and what it called ill-treatment of directors and staff of local libraries at a meeting earlier this month. The organization said it was notably concerned by 'the lack of discussion about how the board will codify this new definition into the APLS administrative state code,' referring to a letter that APLS Board Chair John Wahl sent to local libraries to further clarify definitions related to sexually explicit materials after the board approved the update during a meeting on May 8. 'That is just one of many questions we have about this memo, and we hope to learn the answers in the coming days,' the letter said. SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX Wahl said in an interview Tuesday that several local libraries approached the APLS asking for additional clarification regarding the definition. 'We wanted to be very clear with what we felt our definition was so local libraries would have the information they needed to comply with state code,' he said. 'I can't imagine why anyone would be upset with having more information.' The organization also criticized how some members of the APLS board responded to statements made by local library staff, characterizing the comments that were made to library directors, librarians and supporters of libraries as 'discourteous and dismissive.' A part of ALLA's statement referred to a letter that Wahl sent May 12 to inform local libraries that board members approved an update to its policies that further defines 'sexually explicit' content. These include books or materials that include descriptions of sexual activity, from sexual excitement and nudity to masturbation and sadistic or masochistic abuse. 'This definition is based on existing state and federal guidelines and is intended to serve as a clear and practical reference as you address this matter in your libraries,' Wahl stated in his letter to local library directors. The correspondence stemmed from actions that board members took at the May 8 meeting to further explain the meaning of sexually explicit materials after the board fielded comments about how vaguely the term was defined in the policies. The ALLA executive council also recommended that APLS withdraw Wahl's memo. 'If the APLS is to pursue further policy requirements of Alabama libraries, follow established legal procedure for amending the Administrative Code, with appropriate public comment opportunities and thorough consideration of the constitutionality of both memos,' ALLA said in its statement. The organization also wants APLS to issue an apology to local library staff and directors as well as host a session to field comments from public librarians. Wahl said that board members were respectful to speakers and said multiple times how much he and the other board members cared about local libraries, going so far as to secure funding that the state stands to lose from the federal government. 'There has to be dialogue, and if someone presents information that is factually incorrect, that leaves out entirely, one side of the narrative, it is entirely appropriate for the Board to address that immediately,' Wahl said. Wahl proposed an update to the policy based on a different section of state statute that also includes adult bookstores. The policy update was authorized more than a year after members of the APLS board issued directives to local libraries to adopt regulations to further restrict minors from having access to some library materials. A May 2024 update of the code required libraries to relocate materials within their circulation that have obscenity, are sexually explicit, or ones deemed inappropriate for minors. Obscenity is a legal term and is further defined in state statute. Wahl and other board members said they believe the term 'sexually explicit' needed additional clarification. The APLS board did not update what the term 'inappropriate' during the May 8 meeting. Legislators sponsored bills and Gov. Kay Ivey sent several letters to the APLS aimed at further limiting access to materials for minors. Several bills that would have affected library operations failed to pass the Legislature this year. SUPPORT: YOU MAKE OUR WORK POSSIBLE
Time of India
17-05-2025
- General
- Time of India
Arunachal society to honour Ramchandra Chutia & Ashok Pandey with literary award
Itanagar: The Arunachal Pradesh Literary Society (APLS) will confer the Luminous Lummer Dai Literary Award to Ramchandra Chutia and Dr Ashok Kumar Pandey for 2025. The award will be presented on 85th birth anniversary of the doyen of Arunachal literature, Lummer Dai, on June 1 at Lummer Dai Bhavan, Tezpur, Assam. A selection committee comprising chairman H Rokom Bado and members Banta Natung and Gumpu Nguso recommended their names. Ramchandra Chutia, born in Assam's Dhakuakhana in 1952, has penned 29 books, including eight on socio-anthropological aspects of different tribes of Arunachal Pradesh. His literary works contain a variety of genres such as poems, novels, short stories, travelogues, articles and memories in both Assamese and English. He served in Arunachal Pradesh as a primary school teacher at Sartam village in Tali circle in 1971 and retired as the principal of a govt higher secondary school, Doimukh, in 2010, after serving for 40 years. Dr Ashok Pandey, associate professor in the department of commerce at Dera Natung Govt College, Itanagar, has written 11 books. Born in Uttar Pradesh in 1967, he came to Arunachal in 1992. His literary works include poetry, short stories and drama. Pandey is also a prominent academic writer and his five academic books have been widely appreciated. Since its inception in 2016, 11 prominent writers have been conferred the prestigious award, including Kaling Borang (2016), Mamamg Dai (2017), Dr Jogendra Nath (2018), Tagang Taki (2019), Chandra Kanta Borpatra Gohain and Ramendra Nath Koley (2020 jointly), Yumlam Tana (2021), Ajanta (2022), Jumsi Siram (2023) and Wangsam Zongsam and Thajam Aboh (2024 jointly).
Business Insider
15-05-2025
- Business
- Business Insider
Bank of America Securities Sticks to Their Hold Rating for Apellis Pharmaceuticals (APLS)
In a report released yesterday, Tazeen Ahmad from Bank of America Securities reiterated a Hold rating on Apellis Pharmaceuticals (APLS – Research Report), with a price target of $23.00. The company's shares closed yesterday at $16.70. Confident Investing Starts Here: Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter Ahmad covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, PTC Therapeutics, and Alnylam Pharma. According to TipRanks, Ahmad has an average return of -5.3% and a 43.00% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Apellis Pharmaceuticals with a $37.50 average price target, which is a 124.55% upside from current levels. In a report released yesterday, Mizuho Securities also maintained a Hold rating on the stock with a $20.00 price target. APLS market cap is currently $2.2B and has a P/E ratio of -9.64. Based on the recent corporate insider activity of 69 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of APLS in relation to earlier this year. Most recently, in March 2025, James George Chopas, the VP of APLS sold 183.00 shares for a total of $4,542.06.
